Advances in Aggrephagy: Mechanisms, Disease Implications, and Therapeutic Strategies
- PMID: 39749851
- DOI: 10.1002/jcp.31512
Advances in Aggrephagy: Mechanisms, Disease Implications, and Therapeutic Strategies
Abstract
The accumulation of misfolded proteins within cells leads to the formation of protein aggregates that disrupt normal cellular functions and contribute to a range of human pathologies, notably neurodegenerative disorders. Consequently, the investigation into the mechanisms of aggregate formation and their subsequent clearance is of considerable importance for the development of therapeutic strategies. The clearance of protein aggregates is predominantly achieved via the autophagy-lysosomal pathway, a process known as aggrephagy. In this pathway, autophagosome biogenesis and lysosomal digestion provide necessary conditions for the clearance of protein aggregates, while autophagy receptors such as P62, NBR1, TAX1BP1, TOLLIP, and CCT2 facilitate the recognition of protein aggregates by the autophagy machinery, playing a pivotal role in their degradation. This review will introduce the mechanisms of aggregate formation, progression, and degradation, with particular emphasis on advances in aggrephagy, providing insights for aggregates-related diseases and the development of novel therapeutic strategies.
Keywords: aggrephagy; aggrephagy receptors; autophagy; neurodegeneration; protein aggregates.
© 2024 Wiley Periodicals LLC.
Similar articles
-
CCT2 is an aggrephagy receptor for clearance of solid protein aggregates.Cell. 2022 Apr 14;185(8):1325-1345.e22. doi: 10.1016/j.cell.2022.03.005. Epub 2022 Apr 1. Cell. 2022. PMID: 35366418
-
Neurodegenerative diseases: model organisms, pathology and autophagy.J Genet. 2018 Jul;97(3):679-701. J Genet. 2018. PMID: 30027903 Review.
-
CCT2, a newly identified aggrephagy receptor in mammals, specifically mediates the autophagic clearance of solid protein aggregates.Autophagy. 2022 Jul;18(7):1483-1485. doi: 10.1080/15548627.2022.2083305. Epub 2022 Jun 14. Autophagy. 2022. PMID: 35699934 Free PMC article.
-
Digest it all: the lysosomal turnover of cytoplasmic aggregates.Trends Biochem Sci. 2023 Mar;48(3):216-228. doi: 10.1016/j.tibs.2022.09.012. Epub 2022 Oct 21. Trends Biochem Sci. 2023. PMID: 36280494 Review.
-
Loss of TAX1BP1-Directed Autophagy Results in Protein Aggregate Accumulation in the Brain.Mol Cell. 2020 Dec 3;80(5):779-795.e10. doi: 10.1016/j.molcel.2020.10.041. Epub 2020 Nov 17. Mol Cell. 2020. PMID: 33207181 Free PMC article.
References
-
- Accardi, F., D. Toscani, F. Costa, F. Aversa, and N. Giuliani. 2018. “The Proteasome and Myeloma‐Associated Bone Disease.” Calcified Tissue International 102: 210–226.
-
- Amaro, I. A., and L. A. Henderson. 2016. “An Intrabody Drug (rAAV6‐INT41) Reduces the Binding of N‐Terminal Huntingtin Fragment(s) to DNA to Basal Levels in PC12 Cells and Delays Cognitive Loss in the R6/2 Animal Model.” Journal of Neurodegenerative Diseases 2016: 7120753.
-
- Anguiano, J., T. P. Garner, M. Mahalingam, B. C. Das, E. Gavathiotis, and A. M. Cuervo. 2013. “Chemical Modulation of Chaperone‐Mediated Autophagy by Retinoic Acid Derivatives.” Nature Chemical Biology 9: 374–382.
-
- Atik, A., T. Stewart, and J. Zhang. 2016. “Alpha‐Synuclein as a Biomarker for Parkinson's Disease.” Brain Pathology 26: 410–418.
-
- Baker, B., S. Geng, K. Chen, et al. 2015. “Alteration of Lysosome Fusion and Low‐Grade Inflammation Mediated By Super‐Low‐Dose Endotoxin.” Journal of Biological Chemistry 290: 6670–6678.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous